Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerabilit ...

Eli Lilly (LLY) said on Thursday that eloralintide, its experimental amylin receptor agonist for obesity, helped patients ...

Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase ...

US-based medicine company Eli Lilly to invest $3B in a new manufacturing facility in the Netherlands to expand production and ...